USANA Health Sciences (NYSE:USNA) CFO G Doug Iiekking sold 510 shares of the business’s stock in a transaction that occurred on Wednesday, May 2nd. The stock was sold at an average price of $105.54, for a total value of $53,825.40. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
G Doug Iiekking also recently made the following trade(s):
- On Wednesday, March 7th, G Doug Iiekking sold 2,423 shares of USANA Health Sciences stock. The stock was sold at an average price of $81.05, for a total value of $196,384.15.
Shares of NYSE:USNA traded up $2.30 during trading on Friday, reaching $109.85. 50,998 shares of the stock were exchanged, compared to its average volume of 127,601. USANA Health Sciences has a 12 month low of $52.80 and a 12 month high of $110.30. The stock has a market cap of $2,542.02, a PE ratio of 27.00 and a beta of 0.76.
USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, April 24th. The company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.14. USANA Health Sciences had a net margin of 6.47% and a return on equity of 28.51%. The company had revenue of $292.00 million during the quarter, compared to the consensus estimate of $268.93 million. During the same period in the previous year, the business earned $0.91 earnings per share. The firm’s quarterly revenue was up 14.4% on a year-over-year basis. analysts forecast that USANA Health Sciences will post 4.4 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ifrah Financial Services Inc. raised its position in shares of USANA Health Sciences by 20.4% in the first quarter. Ifrah Financial Services Inc. now owns 4,515 shares of the company’s stock valued at $388,000 after buying an additional 766 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of USANA Health Sciences by 6.4% in the third quarter. JPMorgan Chase & Co. now owns 17,440 shares of the company’s stock valued at $1,005,000 after buying an additional 1,055 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of USANA Health Sciences in the first quarter valued at approximately $137,000. Swiss National Bank raised its position in shares of USANA Health Sciences by 10.1% in the fourth quarter. Swiss National Bank now owns 19,600 shares of the company’s stock valued at $1,451,000 after buying an additional 1,800 shares in the last quarter. Finally, US Bancorp DE raised its position in shares of USANA Health Sciences by 730.1% in the fourth quarter. US Bancorp DE now owns 2,374 shares of the company’s stock valued at $176,000 after buying an additional 2,088 shares in the last quarter. Institutional investors own 49.41% of the company’s stock.
A number of equities research analysts have recently issued reports on the company. TheStreet cut USANA Health Sciences from a “b+” rating to a “c+” rating in a report on Tuesday, February 6th. ValuEngine upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Wednesday. Pivotal Research boosted their price objective on USANA Health Sciences from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, Sidoti cut USANA Health Sciences from a “buy” rating to a “neutral” rating in a report on Wednesday, January 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. USANA Health Sciences currently has a consensus rating of “Hold” and a consensus target price of $95.00.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.